GE Healthcare Technologies Inc., a medical technology company based in the United States, is currently evaluating the sale of a portion of its stake in its Chinese subsidiary, with a valuation potentially reaching several billion dollars. This move reflects the policy pressure and operational challenges faced by foreign medical enterprises in China.
According to reports from Bloomberg on Thursday, GE Healthcare is currently working with financial advisors to explore various options, including selling a portion of its stake, but no final decision has been made yet. Following this news, the company’s stock price rose by 2.3% in pre-market trading. GE Healthcare is currently valued at around $35 billion, with a decrease of approximately 2% so far this year.
Headquartered in Chicago, GE Healthcare stated that despite reviewing its business strategy in China, the company remains “committed to serving Chinese patients and healthcare institutions.” China is its second-largest market with around 7,000 employees.
According to the company’s 2024 annual report, GE Healthcare’s revenue in the Chinese market last year was $2.4 billion, a 15% decrease from 2023. In the quarter ending in June 2025, revenue in China further declined by 3%. The company pointed out that the Chinese government’s anti-corruption actions within the medical industry led to delays in orders and slowed sales.
Medical industry media such as Fierce Biotech and “Business Standard” have noted that this anti-corruption crackdown has severely impacted corporate trust and procurement processes, with foreign enterprises facing compliance pressures and decision delays. GE Healthcare’s consideration of adjusting its stake reflects the continued increase in operational uncertainty for foreign medical companies in China.
Furthermore, geopolitical tensions, intensified local competition, and a slowdown in China’s economic growth are also eroding confidence in American companies’ investments in China. According to a survey released by the American Chamber of Commerce in Shanghai last week, the percentage of U.S. companies optimistic about their China business in the next five years has dropped to 41%, hitting a historical low.
Bloomberg reports suggest that GE Healthcare may address current market challenges by introducing strategic investments or selling off some assets, aligning with the trend of recent strategic adjustments by many multinational companies in China.
Companies such as Starbucks, Häagen-Dazs under General Mills, Decathlon, and the parent company of Burger King, Restaurant Brands International, are also evaluating their business operations and asset allocations in China.
On Tuesday this week, pharmaceutical company Bristol Myers Squibb announced that it would sell its 60% stake in its joint venture in China as part of its global restructuring strategy.